23 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 23 of 23 clinical reviews.
A guide to tesamorelin (Egrifta) interactions with anesthesia and perioperative care, including when to hold the dose, GH-axis effects, glucose management, and alcohol considerations.
Clinical review of the tesamorelin-apixaban drug interaction covering CYP3A4/P-gp mechanism, severity rating, monitoring parameters, and dose-adjustment guidance.
A guide to the tesamorelin and atorvastatin drug interaction, covering mechanism, severity, monitoring parameters, dose considerations, and patient counseling for HIV-associated lipodystrophy.
A guide to the tesamorelin, benzodiazepine drug interaction, covering mechanism, severity, monitoring parameters, dose considerations, and patient counseling for HIV-associated lipodystrophy.
Clinical analysis of the tesamorelin-clopidogrel drug interaction, covering CYP enzyme pathways, cardiovascular risk in HIV lipodystrophy, monitoring protocols, and dose-adjustment guidance.
A clinician-level review of the tesamorelin and diphenhydramine drug interaction, covering mechanism, severity, GH-axis effects, anticholinergic overlap, monitoring parameters, and patient counseling for HIV-associated lipodystrophy management.
What is known and unknown about using tesamorelin with estradiol, including label-based risks, growth-hormone biology, and questions for the prescribing team.
A guide to the tesamorelin, gabapentin drug interaction: mechanism, severity, monitoring parameters, dose considerations, and patient counseling for HIV-associated lipodystrophy.
Clinical guide to combining tesamorelin (Egrifta) with NSAIDs like ibuprofen and naproxen. Covers pharmacokinetic and pharmacodynamic overlap, monitoring recommendations, and dose-adjustment considerations for patients with HIV-associated lipodystrophy.
A clinical deep-dive into the tesamorelin-PPI interaction: mechanism, severity, monitoring parameters, dose adjustments, and patient counseling backed by FDA labeling and primary literature.
A clinical review of the pharmacodynamic interaction between tesamorelin (Egrifta) and prednisone, covering glucose risk, body composition, bone effects, monitoring, and what remains unverified.
A detailed clinical review of the tesamorelin, progesterone HRT drug interaction, covering mechanism, severity, monitoring, dose adjustment, and patient counseling backed by primary literature and FDA labeling.
Can you take Egrifta (tesamorelin) with rivaroxaban? A guide covering CYP3A4 mechanisms, severity ratings, monitoring protocols, and dose-adjustment considerations.
A clinician-level review of the tesamorelin, rosuvastatin drug interaction: mechanism, severity, monitoring parameters, dose adjustments, and patient counseling for HIV-associated lipodystrophy.
Is it safe to take Egrifta (tesamorelin) with sildenafil? A guide covering drug interaction mechanisms, monitoring requirements, dose adjustments, and clinical evidence for combining these medications.
A clinician-level review of the tesamorelin, SNRI interaction covering mechanism, pharmacokinetics, serotonin-syndrome risk, blood-pressure effects, monitoring parameters, and patient counseling for safe co-administration.
Can you take tesamorelin with SSRIs like sertraline or escitalopram? Review the pharmacokinetic and pharmacodynamic evidence, monitoring protocols, and clinical guidance for this combination.
Can you take Egrifta (tesamorelin) with tadalafil? A guide covering pharmacokinetic and pharmacodynamic interactions, monitoring protocols, and dose-adjustment considerations.
What current labeling and interaction resources establish about tesamorelin with trazodone, what remains unknown, and which patient-specific risks require review.
A clinician-level review of the tesamorelin-warfarin drug interaction: mechanism, INR monitoring, dose adjustment, and patient counseling backed by FDA labeling and primary literature.
A clinical review of the tesamorelin (Egrifta) and zolpidem drug interaction, covering pharmacokinetic and pharmacodynamic mechanisms, severity rating, monitoring parameters, dose adjustments, and patient counseling.
A guide to how nicotine affects tesamorelin (Egrifta) efficacy, GH axis suppression, metabolic outcomes, and what patients on TRT or peptide therapy need to know before combining the two.
The current tesamorelin label does not list a levothyroxine interaction. See what was studied, what remains unknown, and how thyroid monitoring fits.